Why Iradimed Stock Soared Today

Core Viewpoint - Iradimed has achieved significant financial growth, setting a new all-time high in revenue for the 18th consecutive quarter, with both revenue and net income increasing at double-digit rates, leading to a nearly 10% rise in stock price on the announcement day [1]. Financial Performance - In Q4 2025, Iradimed reported revenue of $22.7 million, a 17% increase compared to Q4 2024. Net income rose 23% to just under $7 million, equating to $0.54 per share [2]. - The company exceeded consensus analyst estimates for earnings per share, which was projected at $0.48 [3]. Product Development - Iradimed's growth was bolstered by the launch of a new product, the 3870 intravenous infusion pump, which began shipping during the quarter [4]. Dividend Announcement - The company announced an increase in its quarterly dividend from $0.17 to $0.20 per share, effective March 6 for investors of record as of February 23 [5]. Future Guidance - For the full year 2026, Iradimed projects revenue between $91 million and $96 million, with non-GAAP net income expected to be between $2.06 and $2.21 per share, both significantly higher than the 2024 figures of $73 million in revenue and $1.66 per share adjusted net profit [6]. Market Position - Iradimed is positioned as a strong player in the niche medical devices segment, particularly in MRI-compatible equipment, indicating a continued growth trajectory [7].